THE DEFINITIVE SOURCE OF
Our deep industry knowledge and analytical expertise allow us to create the highest quality consensus forecasts and give our clients solid benchmarks for their strategic decisions.
Unique to the market as the largest back catalogue of consensus drug forecasts, Evaluate's archived consensus forecasts cover 1.5m+ forecasts across 10,000+ drugs, dated back to January 2003. Analyse drug progression across monthly archives and use it in coordination with EventAnalyzer to understand the news events that led to consensus forecast changes.
Track thousands of deals by company, product, therapy area, compound phase, deal value and much more. Evaluate maintains historic deal data as well as venture financing and IPO information across pharmaceutical and biotech companies. Analyse, in conjunction, key patent expiration dates and the worldwide and US sales at risk.
Includes financial metrics by company: aggregated profit and loss to 2026, CAGRs ranked, comparison by reported income.
Event Analyzer is a daily and weekly round-up of the stock price winners and losers and the underlying news events impacting the pharmaceutical and biotech company share prices and valuations.
Calendar of Events offers daily insights and email alerts with insight into future critical events related to a product's life cycle and provides company guidance around development and regulatory timelines.
Evaluate Omnium's success rates predict which in-house or competitor drugs are most likely to reach the market, so you can compare risk levels across products or indications. Includes product-specific probability of technical and regulatory success (PTRS), fully transparent risk audits and success rate benchmarks.
Our R&D costs provides the industry’s first comprehensive clinical trial costing model, applying real-world data to over 50,000 trials, so you can better assess likely costs across the development cycle. Includes estimated, product-level trial costs for past and current clinical trials, future R&D cost predictions and industry benchmarks by indication.
Calculates a product’s Net Present Value (NPV) using an interactive model based on discounted cash flow models to 2040 for over 6,000 products, with editable inputs so you can create custom models.
Evaluate Omnium NPV Analyzer model also extends to the indication level, with increased granularity on inputs and cashflow by indication, improving your understanding of product value drivers.
Evaluate Omnium aggregates key pricing data, so you have easy access to consolidated, standardised US pack pricing for approved products, current cost-per-patient values for launched products and benchmarks for annual cost-per-patient by indication and technology.
Our Market Access data provides unique formulary access scores to help you identify the current market access position for products launched in the US, with benchmarks by EphMRA code, technology and mechanism of action.
Provides time-to-peak analysis so you can better assess a drug’s market impact or improve product launch planning. Includes US time-to-peak benchmarks by indication, market exclusivity impact and time-to-peak values for historically launched drugs.
Predicts when key development milestones will occur, so you can track progress against competitors or highlight products with first-in-class potential. Includes time-in-phase, launch date and market entry order predictions, as well as recruitment timeline benchmarks.
Tracks and integrates clinical trials from three key industry sources alongside key commercial insights, so you can fully understand company development plans and pipelines.
Our predictive clinical trial design anticipates future patient enrolment needed to successfully complete clinical development, so you can determine trial resources needed, alongside historical benchmarks by phase and indication.
Aggregates and standardises clinical trial outcomes for indications and products so you can stay informed on trial results, updated daily and focused on the indication-specific endpoints most likely to lead to regulatory approval.
Predicted peak sales delivers an independent, balanced view of asset potential with comprehensive coverage across all phases of the clinical lifecycle, including early-stage and privately-owned drugs, so you can identify the products with the greatest commercial potential.
Risk-adjusted peak sales combine improved accuracy of our Product Specific PTRS with Predicted Peak Sales analytics, so you have a single metric for forecasting the commercial potential of pharma assets across all phases of clinical development.
Quantifies and compares the degree of unmet need across indications, so you can better focus portfolio investments on therapeutic areas that could have the greatest impact to patients.
“ Many of Genentech's products have multiple indications, so Evaluate's sales by indication gives us unique insight into what is driving sales or growth of a product, and saves us significant time. ”
“ Evaluate is such an important resource for us; it makes all of our lives easier when we can find the information we need in ten minutes in Evaluate, rather than spending 24 - 48 hours manually searching. ”